Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more
3060 Pegasus Park Drive, Dallas, TX, 75247, United States
Market Cap
674.7M
52 Wk Range
$4.90 - $35.80
Previous Close
$34.43
Open
$34.50
Volume
105,712
Day Range
$33.00 - $34.82
Enterprise Value
597.7M
Cash
76.96M
Avg Qtr Burn
-16.47M
Insider Ownership
2.36%
Institutional Own.
67.17%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
FB102 Details Celiac Disease | Phase 2 Data readout | |
FB102 (Anti-CD122 Antibody) Details Alopecia Areata | Phase 1b Data readout | |
FB102 (Anti-CD122 Antibody) Details Vitiligo | Phase 1b Data readout | |
FB102 Details Graft-versus-host disease | Phase 1 Data readout |
